Similar to RUNX1, the strongest evidence for a pro-oncogenic function for RUNX2 comes from studies in lymphoma/leukemia models [26]; however RUNX2 was also shown to play a role in invasive bone [27], breast [28], prostate [29], thyroid [30] and pancreatic cancer [31]. Here, RUNX2 is linked to familial pancreatic carcinoma.